ATE237321T1 - 20-hete antagonisten und agonisten - Google Patents

20-hete antagonisten und agonisten

Info

Publication number
ATE237321T1
ATE237321T1 AT99908425T AT99908425T ATE237321T1 AT E237321 T1 ATE237321 T1 AT E237321T1 AT 99908425 T AT99908425 T AT 99908425T AT 99908425 T AT99908425 T AT 99908425T AT E237321 T1 ATE237321 T1 AT E237321T1
Authority
AT
Austria
Prior art keywords
hete
agonists
antagonists
acid
hydroxyeicosa
Prior art date
Application number
AT99908425T
Other languages
English (en)
Inventor
Richard J Roman
John R Falck
Magdalena Alonso-Galicia
Elizabeth R Jacobs
David R Harder
Original Assignee
Mcw Res Found Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcw Res Found Inc, Univ Texas filed Critical Mcw Res Found Inc
Application granted granted Critical
Publication of ATE237321T1 publication Critical patent/ATE237321T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
AT99908425T 1998-02-26 1999-02-24 20-hete antagonisten und agonisten ATE237321T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7609198P 1998-02-26 1998-02-26
PCT/US1999/004020 WO1999043310A2 (en) 1998-02-26 1999-02-24 20-hete antagonists and agonists

Publications (1)

Publication Number Publication Date
ATE237321T1 true ATE237321T1 (de) 2003-05-15

Family

ID=22129876

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99908425T ATE237321T1 (de) 1998-02-26 1999-02-24 20-hete antagonisten und agonisten

Country Status (13)

Country Link
US (3) US6395781B1 (de)
EP (1) EP1056449B1 (de)
JP (1) JP3921583B2 (de)
KR (1) KR100390312B1 (de)
CN (1) CN1148179C (de)
AT (1) ATE237321T1 (de)
AU (1) AU750579B2 (de)
CA (1) CA2320706C (de)
DE (1) DE69906944T2 (de)
DK (1) DK1056449T3 (de)
ES (1) ES2194444T3 (de)
PT (1) PT1056449E (de)
WO (1) WO1999043310A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395781B1 (en) * 1998-02-26 2002-05-28 Mcw Research Foundation 20-HETE antagonists and agonists
US8722668B2 (en) * 1998-12-23 2014-05-13 Daryl W. Hochman Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
US7214711B2 (en) * 1998-12-23 2007-05-08 Neurotherapeutics Pharma Llc Method of treating migraine headache without aura
US8008283B2 (en) * 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
ES2256053T3 (es) * 1999-11-01 2006-07-16 Taisho Pharmaceutical Co., Ltd Inhibidor de la enzima de produccion de 20-hete.
JP2004512361A (ja) * 2000-11-03 2004-04-22 エムシーダブリユー　リサーチ　フオンデーシヨン　インコーポレーテツド 脳血管疾患治療法としての２０−ｈｅｔｅ合成酵素阻害薬の使用
AU2002246926A1 (en) * 2001-01-02 2002-08-06 New York Medical College 12-hydroxy-eicosatrienoic acid analogs and methods of use thereof
US7214714B2 (en) 2001-04-26 2007-05-08 Taisho Pharmaceutical Co. Ltd. 20-hydroxyeicosatetraenoic acid production inhibitors
US6818662B2 (en) * 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
WO2003105831A1 (en) * 2002-06-14 2003-12-24 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat ophthalmic inflammatory disorders
CA2545364A1 (en) * 2003-11-14 2005-05-26 Mcw Research Foundation, Inc. Methods of modulating angiogenesis and cancer cell proliferation
US20060063836A1 (en) * 2004-09-16 2006-03-23 Roman Richard J Method for treating renal disease
US20080306155A1 (en) * 2004-09-16 2008-12-11 Roman Richard J Method for treating renal disease
US20070004802A1 (en) * 2004-09-16 2007-01-04 Roman Richard J Method for treating renal disease
US20070149526A1 (en) * 2005-10-17 2007-06-28 Neurotherapeutics Pharma, L.L.C. Diuretic and diuretic-like compound analogs
WO2008034011A2 (en) 2006-09-13 2008-03-20 Mcw Research Foundation, Inc. Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases
US20090069418A1 (en) * 2007-04-25 2009-03-12 Alkayed Nabil J Compositions and Methods for the Treatment of Disorders Associated with Aberrant Vasodilation
EP2208720A1 (de) * 2009-01-13 2010-07-21 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Neuartige Eicosanoidderivate
ES2732310T3 (es) * 2013-12-10 2019-11-21 Univ California Diagnóstico diferencial de enfermedad hepática
PT3097076T (pt) 2014-01-22 2019-07-30 Max Delbrueck Centrum Fuer Molekulare Medizin Novos derivados cyp-eicosanoides
WO2017156164A1 (en) * 2016-03-09 2017-09-14 Board Of Regents, The University Of Texas System 20-hete receptor (gpr75) antagonists and methods of use
CA234980S (en) * 2024-04-16 2025-12-03 Fk Europe S R L Seat part of chair

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334736A (en) 1991-05-16 1994-08-02 University Of Texas System Board Of Regents Functionalizing carbohydrate derivatives by base-induced β-eliminatiom forming bioactive derivatives containing hydroxy-diene subunits
US5502226A (en) * 1994-11-14 1996-03-26 Elizabeth Arden Co., Division Of Conopco, Inc. Process of preparing ω-hydroxy acids
US5753702A (en) 1996-05-22 1998-05-19 University Of Vermont Arachidonic acid metabolite, 16-hete
US6395781B1 (en) * 1998-02-26 2002-05-28 Mcw Research Foundation 20-HETE antagonists and agonists

Also Published As

Publication number Publication date
CA2320706C (en) 2007-05-01
US20020049244A1 (en) 2002-04-25
CN1148179C (zh) 2004-05-05
DK1056449T3 (da) 2003-08-11
PT1056449E (pt) 2003-09-30
ES2194444T3 (es) 2003-11-16
US6596769B2 (en) 2003-07-22
DE69906944D1 (de) 2003-05-22
EP1056449B1 (de) 2003-04-16
WO1999043310A2 (en) 1999-09-02
DE69906944T2 (de) 2003-12-24
EP1056449A2 (de) 2000-12-06
AU750579B2 (en) 2002-07-25
CN1291890A (zh) 2001-04-18
JP3921583B2 (ja) 2007-05-30
US6395781B1 (en) 2002-05-28
WO1999043310A3 (en) 1999-10-07
US6605641B2 (en) 2003-08-12
US20020072534A1 (en) 2002-06-13
KR100390312B1 (ko) 2003-07-12
JP2003522098A (ja) 2003-07-22
KR20010034544A (ko) 2001-04-25
AU2786199A (en) 1999-09-15
CA2320706A1 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
DE69906944D1 (de) 20-hete antagonisten und agonisten
DK1104425T3 (da) Hidtil ukendte thiazolopyrimidinforbindelser
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
BR9916896A (pt) Diaril aminas substituìdas com 1-heterociclo
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
ATE351907T1 (de) Selective il-2 agonisten und antagonisten
NO994906D0 (no) GnRH antagonister som er modifisert i stillinger 5 og 6
YU15299A (sh) Farmaceutski sastavi
ATE345133T1 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
IT8323205A0 (it) Composizioni farmaceutiche adattivita' antiinfiammatoria e/o analgesica, non ulcerogene.
BG105256A (en) Muscarinic agonists and antagonists
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
BR9813817A (pt) Análogos de hemiasterlina
BG101401A (bg) Състави за орално приложение с удължено освобождаване на цисаприд
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
PT929299E (pt) 1,2,3,4-tetra-hidro-2-dibenzofuranaminas e 2-aminociclo-hepta ¬b| benzofuranos substituidos
ATE28188T1 (de) Antikonvulsive mittel.
GB9811221D0 (en) Bacterial-pheromones and uses therefor
ES2152315T3 (es) Xamoneline tartrato.
AU580890B2 (en) P-acylaminobenzamides
IL106237A0 (en) Piperidyl amides,sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis
DK1011329T3 (da) 7-Methylthiooxomethyl- og 7-methylthiodioxomethyl-paclitaxeler
ITTO940212V0 (it) Attrezzatura per compassi sostitutiva dell'ago.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1056449

Country of ref document: EP

REN Ceased due to non-payment of the annual fee